Smith & Nephew plc — Cyborg Score 7/10

Strong
Medical Devices & Healthcare Technology

Strategic Profile

The company's new RISE framework is designed to accelerate growth, expand margins and improve operational efficiency to strengthen shareholder returns. Smith & Nephew has outperformed peers, driven by strong sports medicine and wound care, despite ongoing ortho business challenges, with management executing a focused turnaround under CEO Deepak Nath.

Cyborg Score Rationale

2025 has been one of Smith & Nephew's most stable periods in recent years, with the company delivering year-on-year growth across all three major segments. The company set out 2028 objectives including 6-7% underlying revenue CAGR, 9-10% trading profit CAGR and 12-13% post-tax ROIC, though valuation risk exists with trailing P/E near 60x.

Top Insights

  • 2026 guidance projects around 6% underlying revenue growth, profit growth ahead of sales, and free cash flow of roughly $800 million
  • Portfolio rationalization expected to reduce gross inventory by about $500 million and create a non-cash provision of roughly $200 million in 2025
  • UFC partnership multi-year extension announced October 2025, with the second Smith+Nephew UFC Combat Sports Medicine Course held in Las Vegas February 18-20, 2026
  • Integrity Orthopaedics acquisition announced January 2026 to bolster shoulder repair portfolio

Named Competitors

  • Stryker Orthopaedic Platforms — Leading orthopaedic and trauma implant manufacturer
  • Zimmer Biomet Orthopedic Portfolio — Major knee and hip implant competitor
  • Arthrex Sports Medicine — Sports medicine and soft tissue repair leader
  • Medtronic Wound Care — Advanced wound management and therapies

Recent Developments

  • (January 2026) Acquired Integrity Orthopaedics to expand shoulder repair capabilities
  • (December 2025) Announced RISE strategy with 2028 targets at Capital Markets Day
  • (October 2025) Extended UFC partnership as preferred sports medicine technology partner
  • (December 2025) Issued 2026 provisional guidance for 6% revenue growth and $800M free cash flow

Open the full interactive Smith & Nephew plc report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →